Dogness (DOGZ) : 7-year performance

Dogness (International) Corporation, through its subsidiaries, designs, manufactures, and sells fashionable products for dogs and cats worldwide. The company provides pet leashes, pet collars, pet harnesses, and retractable leashes, as well as lanyards; gift suspenders, pet belt ribbons, laces, elastic belts, computer jacquard ribbons, and high-grade textile laces; climbing hooks; and intelligent and entertaining pet products.

Ticker: DOGZ 

IPO: Dec 20, 2017

• Sector: Consumer Cyclical
• Industry: Leisure
• Full Time Employees: 197
• founded in 2003 and is headquartered in Dongguan, the People's Republic of China
• https://webus.dogness.com/index?lang=en

MeiraGTx (MGTX) $200M deal with Hologen AI for Parkinson's therapy

 

 

 

 

 

 

IPO: June 8, 2018

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond

MeiraGTx will partner with Hologen AI to leverage its multimodal generative AI (genAI) models to accelerate Phase III development of the biotech's AAV-GAD gene therapy for Parkinson’s disease. 

The therapy, dubbed AAV-GAD, delivers a gene that codes for the enzyme that makes the neurotransmitter GABA, which is implicated in the characteristic motor dysfunction of Parkinson’s. A small-scale phase 2 readout last October showed that AAV-GAD was able to improve patients' motor ability and quality of life.

Details of the agreement 

MeiraGTx will receive an upfront cash payment of $200 million from Hologen, and together, the partners will launch a joint venture called Hologen Neuro AI. The genAI firm will also contribute $230 million in funding for the JV, which will shepherd AAV-GAD through development to commercialisation. The capital will help support other early-stage clinical programmes targeting the central nervous system (CNS), such as AAV-BDNF for genetic obesity. 

MeiraGTx will retain 30% ownership in Hologen Neuro AI and take the lead on all clinical development and manufacturing. It will form exclusive clinical and commercial manufacturing supply agreements with the JV. 

In turn, Hologen will use its genAI tech to optimise MeiraGTx's manufacturing practices, while gaining a minority stake in the manufacturing subsidiary and contributing to annual funding. 

About Hologen 

Hologen Limited is a world-leading developer of generative AI capabilities for clinical medicine and pharmaceutical drug development. 

The company emerged as a spin-out from University College London and Kings College London. It is privately held.

For more information, please visit www.hologen.ai

ADT Inc. (ADT) : 7-year performance

ADT is an American security company that provides alarm monitoring services for homes and small businesses. The company was founded in 1874 as American District Telegraph by Edward A. Calahan.

ADT currently serves more than 7.2 million residential and business customers, making it the largest monitoring and service company in the United States and Canada, supported by approximately 18,000 employees and visiting approximately 10,000 homes and businesses daily. ADT handles an average of 15 million alarms annually and provides support to its clients from over 200 sales and service locations and through its 12 monitoring centers listed by Underwriters Laboratories.        

• In 2012, ADT became an independent public company. 
• In 2016, Apollo Global Management acquired ADT for nearly $7 billion. 
• January 19, 2018: Less than two years after being acquired and merged with Protection 1 by Apollo Global Management in a deal that took the company private, ADT is a publicly-traded company once again following the launch of its initial public offering on the New York Stock Exchange.

Ticker: ADT

January 19, 2018 IPO:  Although ADT had been looking to raise as much as $2.1 billion by offering 111.1 million shares ranging from $17 to $19 each, the company only offered 105 million shares at a price of $14 each, raising only $1.47 billion in the offering.  As of 2023, Apollo still has a majority share in ADT. 

 

 ADT, Inc. Chief Executive Officer Timothy J. Whall, joined by members of ADT's senior executive team and board of directors, rings the NYSE Opening Bell.

Metalpha Technology (MATH) : 7-year performance

Metalpha Technology Holding Limited (MATH) is a Hong Kong-based company that provides wealth management services using digital assets. The company was formerly known as Dragon Victory International Limited and changed its name to Metalpha Technology Holding Limited in November 2022.

• Sector: Financial Services
• Industry: Capital Markets
• digital asset wealth management
• Full Time Employees: 19
• Founded: 2015
• Headquartered: Wan Chai, Hong Kong
• Website: metalpha.net
• Employees 19

IPO on October 20, 2017; opened at $7.39

Nauticus Robotics (KITT) : 7-year performance

Nauticus Robotics, Inc. develops ocean robots, cloud software, and services to the ocean industry.

• Sector: Industrials
• Industry: Aerospace & Defense
• Full Time Employees: 72
• Founded in 2014 
• Headquartered in Webster, Texas
• https://nauticusrobotics.com

IPO July 19, 2021: Nauticus went public following its SPAC (special purpose acquisition company) merger with New York City-based CleanTech Acquisition Corp. the Company sold 15,000,000 Units at a purchase price of $10.00 per Unit.

Safe & Green Holdings (SGBX) : 7-year performance

Safe & Green Holdings Corp. designs and modifies code-engineered cargo shipping containers and purpose-built modules for commercial, industrial, and residential building construction in the United States.

• Sector: Industrials
• Industry: Metal Fabrication
• Full Time Employees: 92
• Founded in 2007 
• Headquartered in Miami, Florida
• https://www.safeandgreenholdings.com

IPO: June 22, 2017

 

 

 

 

Boxlight (BOXL) : 7-year performance

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market.

• Sector: Technology
• Industry: Communication Equipment
• Full Time Employees: 228
• Founded by Herbert Myers and Sloan Myers in 1985 
• Headquartered in Duluth, Georgia
• https://boxlight.com

Boxlight went public on Thursday, November 30, 2017, with the IPO price of $7 per share.

 

 

 

Ecovyst (ECVT) reported earnings on Thur 31 Oct 24 (b/o)

The company was formerly known as PQ Group Holdings Inc. and changed its name to Ecovyst Inc. in August 2021.

• Sector(s): Basic Materials
• Industry: Specialty Chemicals
• Full Time Employees: 911
• Founded in 1831 
• Headquartered in Malvern, Pennsylvania
• https://www.ecovyst.com

** charts 1 day after earnings **

NuCana (NCNA) discontinues Phase II NuTide:323 colorectal cancer study

Scotland-based biotech NuCana has announced that it is discontinuing its NuTide:323 study (NCT05678257).

NuTide:323 was an open-label, dose/schedule optimisation study evaluating the efficacy of NuCana’s NUC-3373 ProTide in combination with leucovorin, irinotecan and bevacizumab (NUFIRI+bev).

• NuCana plc's American Depositary Shares (ADSs) began trading on October 2, 2017. 
• NuCana plc is a clinical-stage biopharmaceutical company that develops new medicines to treat cancer. The company was founded in 1997 by Hugh Stephen Griffith and Christopher Barry Wood and is headquartered in Edinburgh, Scotland. NuCana's ProTide technology transforms widely prescribed chemotherapy agents into safer and more effective medicines.
• GlobalData’s pharmaceutical database shows that NuCana has 13 ProTides in its drug development pipeline, in indications including ovarian cancer, non-small cell lung cancer, and acute lymphocytic leukaemia. 
  
• https://www.nucana.com/

 

 

 

 

WideOpenWest (WOW): 7-year performance

 ticker: WOW

Rekor Systems (REKR) : 7-year performance

Rekor Systems is a traffic services company that offers traditional traffic studies, AI-driven traffic studies, and traffic engineering services.

• Sector: Technology
• Industry: Software - Infrastructure
• Full Time Employees: 347
• Founded by James K. McCarthy
• Incorporated in 2017 
• Headquartered in Columbia, Maryland
• https://www.rekor.ai

Went public on AUg 25, 2017 following the merger of Brekford Traffic Safety, Inc. and KeyStone Solutions, Inc.

 

Snap to lay off 10% of global workforce, around 500 employees

Snap said it will lay off 10% of its workforce worldwide, around 500 employees, to “promote in-person collaboration.”

• The company’s last major round of cuts was in August 2022, when it laid off 20% of staff and restructured its business lines.
• Snap CEO Evan Spiegel testified before the Senate Judiciary Committee last week, one of several social media executives to face scrutiny over the damage their platforms caused young people.
• The social media platform is the latest tech company to continue cutting in 2024. Nearly 24,000 tech workers lost their jobs in January alone. Already this month, cybersecurity and identity company Okta and Zoom have laid off staff.
• Snap stock remains below its debut price and well off its 2021 high of around $83.
  

 

 

Snap announces plans to reduce headcount by approx. 10% of global full time employees; will incur pre-tax charges of $55-$75 mln related to the headcount reduction

• Per a filing, "In order to best position our business to execute on our highest priorities, and to ensure we have the capacity to invest incrementally to support our growth over time, we have made the difficult decision to restructure our team."
• As a result, SNAP currently estimates that it will incur pre-tax charges in the range of $55 million to $75 million, primarily consisting of severance and related costs, and other charges, of which $45 million to $55 million are expected to be future cash expenditures. The majority of these costs are expected to be incurred during the first quarter of 2024. Potential position eliminations in each country are subject to local law and consultation requirements, which may extend this process into the second quarter of 2024 or beyond in certain countries. The charges that they expect to incur are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual expenses may differ materially from the estimates disclosed above.

Kindred Biosciences (KIN) : positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus

  

 

 

 

SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group.

KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE: ELAN).

In this randomized, blinded, placebo-controlled study, KIND-030 was administered to dogs after they tested positive for CPV infection. The primary endpoint of the study was met. The parvovirus challenge resulted in 57% mortality rate in the control dogs compared to 0% mortality rate in the KIND-030 treated dogs. The dogs did not receive any supportive care or other treatments.

"Parvovirus is a devastating disease currently without any available treatment," said KindredBio's Chief Executive Officer, Richard Chin, M.D. "With 100% efficacy, we believe KIND-030 has the potential to revolutionize the care of these dogs. Instead of a lengthy and expensive hospitalization that is frequently ineffective and can leave the dog with permanent disabilities, the infected dogs can now be treated with a single injection without need for additional supportive care or hospitalization."

"We are excited to partner with KindredBio on this revolutionary treatment that can significantly improve the health and well-being of dogs," said Jeff Simmons, president and CEO of Elanco Animal Health. "With our significant global reach and access to veterinarians and pet owners around the world, Elanco looks forward to leveraging our capabilities and skilled team of experts to advance and commercialize this novel treatment for pets globally."

With this positive study, KIND-030 has now demonstrated efficacy in both indications being pursued: prophylactic therapy to prevent clinical signs of canine parvovirus infection, and treatment of established parvovirus infection. Results from the pivotal efficacy study for the therapeutic claim are expected to be submitted to the United States Department of Agriculture (USDA) in June, with possible approval by year-end 2021.

CPV is the most significant and contagious viral cause of enteritis in dogs, especially puppies, with mortality rates as high as 91% if untreated. There are currently no Food and Drug Administration or USDA approved treatments for CPV, nor any other available treatment. Veterinary intervention is limited to supportive care, which can cost owners up to thousands of dollars per puppy, with an average cost of $1,200.

Canine parvovirus is most often seen in puppies less than 6 months of age, but can occur in unvaccinated dogs of any age. Clinical signs often include depression, not eating, vomiting, and profuse diarrhea which is often blood tinged.1 Banfield estimates that there are approximately 250,000 parvo cases in the U.S. each year, excluding emergency hospitals, shelters, specialty hospitals, or undiagnosed cases.2

KIND-030 binds to critical portions of the virus, preventing the virus from entering into cells.

On April 28, 2021 KindredBio announced acceptance of the parvovirus antibody prophylaxis study data and approval of the efficacy indication by the USDA Center for Veterinary Biologics. The pivotal efficacy data for the prophylactic indication demonstrated that 0% of the KIND-030 treated dogs developed parvovirus infection while 100% of the placebo-control dogs developed the disease, and also showed 100% survival rate in KIND-030.

Regulatory approval and review timeline are subject to the typical risks inherent in such a process. The results of the pivotal efficacy study for the therapeutic claim stated in this press release have not been reviewed by the USDA Center for Veterinary Biologics.

Cara Therapeutics (CARA) : Korsuva fails for the treatment in atopic dermatitis (AD) patients

   

 

 

  

 

 

 

 

Cara Therapeutics announces topline results from its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients

Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population.

Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder analysis in pre-specified analyses of mild-to-moderate AD patients (64% of ITT patient population).

Statistically significant improvement in 4-point responder analysis in mild-to-moderate (BSA <10%) AD patients with 32% of KORSUVA-treated patients achieving a > 4-point reduction vs. 19% in placebo group (p=0.03).

KORSUVA was well tolerated at all dose levels.